|
|
|
GRTS Description — Gritstone bio Inc
Gritstone bio is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. Co. discovers, develops, manufactures, and delivers cancer and infectious disease immunotherapy candidates by utilizing both of its vaccine vectors, self-amplifying mRNA and chimpanzee adenovirus. Co.'s oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. Co.'s programs in clinical stage development are: CORAL, a second generation COVID-19 vaccine program and an HIV therapeutic/cure vaccine candidate that Co. is collaborating on with Gilead Sciences, Inc.
Company Name: |
Gritstone bio Inc |
Website: |
www.gritstoneoncology.com |
Sector: |
Biotechnology |
Number of ETFs Holding GRTS: |
12 |
Total Market Value Held by ETFs: |
$6,571,172 |
Total Market Capitalization: |
$96,000,000 |
% of Market Cap. Held by ETFs: |
6.84% |
|
ETF |
GRTS Weight |
GRTS Amount |
VTI |
0.00% |
$2,422,474 |
IWM |
0.00% |
$1,798,731 |
VXF |
0.00% |
$1,096,781 |
IWN |
0.01% |
$723,335 |
VTWO |
0.00% |
$285,266 |
IWC |
0.02% |
$163,282 |
VTWV |
0.01% |
$53,373 |
QQQS |
0.16% |
$12,460 |
URTY |
0.00% |
$6,079 |
VTHR |
0.00% |
$4,671 |
List of all 12 ETFs holding GRTS
» |
|
|
|
|
Strong Buy (4.00 out of 4)
90th percentile
|
|
|